The S-4 effectiveness signals an imminent shareholder vote or closing of a merger/acquisition. Monitor for the definitive proxy statement/prospectus and the terms of the transaction, including exchange ratio and any cash consideration.
How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+5- T+0 · Nov 5 $3.68entry
- T+1 · 11d ago +0.54%α +0.23% · $3.70
- T+5 · 5d ago 0.00%α −3.29% · $3.68
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics received SEC effectiveness for its S-4 registration statement (File No. 333-298705) on November 4, 2026. This allows the company to proceed with the business combination or exchange offer described in the S-4, typically a merger or acquisition involving stock consideration.
Key Facts
- EFFECT notice filed November 5, 2026, with effectiveness date of November 4, 2026
- Registration statement on Form S-4 (File No. 333-298705) declared effective
- S-4 is used for business combinations, exchange offers, or reclassifications involving stock
- Fulcrum Therapeutics is a pharmaceutical company with $279M market cap
Financial Impact
Effectiveness of S-4 enables a business combination; no financial terms disclosed in this filing
Risk Factors
- S-4 effectiveness does not disclose the terms or valuation of the underlying transaction
- Shareholder approval or regulatory conditions may still be pending
- Potential dilution from stock issuance in the business combination
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003437 |
| Document: 9999999995-26-003437-index.html | 9999999995-26-003437 |
| Document: 9999999995-26-003437.txt | 9999999995-26-003437 |
Track record
23 reports on FULC
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Viewing Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers